AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trépanier, E. F.
Right arrow Articles by Amsden, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trépanier, E. F.
Right arrow Articles by Amsden, G. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 1998, p. 695-697, Vol. 42, No. 3
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Effect of Terbinafine on Theophylline Pharmacokinetics in Healthy Volunteers

Eric F. Trépanier,1 Anne N. Nafziger,2,3 and Guy W. Amsden1,2,3,*

Departments of Pharmacy Services1 and Medicine2 and Clinical Pharmacology Research Center,3 Bassett Healthcare, Cooperstown, New York 13326-1394

Received 9 September 1997/Returned for modification 15 November 1997/Accepted 20 December 1997

Twelve healthy volunteers were enrolled in an open-label, randomized, crossover study. Subjects received single doses of theophylline (5 mg/kg) with and without multiple-dose terbinafine, and 11 blood samples were collected over 24 h. The study phases were separated by a 4-week washout period. Theophylline serum data were modeled via noncompartmental analysis. When the control phase (i.e., no terbinafine) was compared to the treatment phase (terbinafine), theophylline exposure (the area under the serum concentration-time curve from time zero to infinity) increased by 16% (P = 0.03), oral clearance decreased by 14% (P = 0.04), and half-life increased by 24% (P = 0.002). No significant changes in other theophylline pharmacokinetic parameters were evident.

* Corresponding author. Mailing address: Clinical Pharmacology Research Center, Department of Pharmacy Services, Bassett Healthcare, One Atwell Rd., Cooperstown, NY 13326-1394. Phone: (607) 547-3680. Fax: (607) 547-3629. E-mail: amsden{at}telenet.net.

Antimicrobial Agents and Chemotherapy, March 1998, p. 695-697, Vol. 42, No. 3
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 1998 by the American Society for Microbiology. All rights reserved.